Потенциальные маркеры ответа на лечение у больных хронической спонтанной крапивницей
https://doi.org/10.26295/OS.2020.22.86.006
Аннотация
Об авторах
Н. О. Переверзина
Federal State Budgetary Educational Institution of additional professional education «Central state Medical Academy for managing affairs of the president of the Russian Federation»
Россия
Россия
Е. О. Грибалева
N. I. Sechenov First Moscow State Medical University
Россия
Россия
А. С. Алленова
N. I. Sechenov First Moscow State Medical University
Россия
Россия
Д. М. Скандер
N. I. Sechenov First Moscow State Medical University
Россия
Россия
П. В. Колхир
N. I. Sechenov First Moscow State Medical University
Россия
Россия
Список литературы
1. Zuberbier T. et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria // Allergy. 2018. Vol. 73, № 7. P. 1393-1414.
2. Asero R. et al. Current challenges and controversies in the management of chronic spontaneous urticaria // Expert Rev Clin Immunol. 2015. Vol. 11, № 10. P. 1073-1082.
3. Silvares M., Fortes M., Miot H. CSU and Angioedema // Rev Assoc Med Bras. 2011. Vol. 57, № 577. P. 82.
4. O’Donnell B. F. et al. The impact of chronic urticaria on the quality of life // Br. J. Dermatol. 1997. Vol. 136, № 2. P. 197-201.
5. Kocatürk E. et al. Looking forward to new targeted treatments for chronic spontaneous urticaria // Clin Transl Allergy. 2017. Vol. 7. P. 1.
6. Guillén-Aguinaga S. et al. Updosing nonsedating antihistamines in patients with chronic spontaneous urticaria: a systematic review and meta-analysis // Br. J. Dermatol. 2016. Vol. 175, № 6. P. 1153-1165.
7. Magen E. et al. Factors related to omalizumab resistance in chronic spontaneous urticaria // Allergy Asthma Proc. 2019. Vol. 40, № 4. P. 273-278.
8. Kulthanan K. et al. Factors Predicting the Response to Cyclosporin Treatment in Patients With Chronic Spontaneous Urticaria: A Systematic Review // Allergy Asthma Immunol Res. 2019. Vol. 11, № 5. P. 736-755.
9. Kolkhir P. et al. Eosinopenia, in Chronic Spontaneous Urticaria, Is Associated with High Disease Activity, Autoimmunity, and Poor Response to Treatment // J Allergy Clin Immunol Pract. 2020. Vol. 8, № 1. P. 318-325.
10. Magen E. et al. Clinical and laboratory features of antihistamine-resistant chronic idiopathic urticaria // Allergy Asthma Proc. 2011. Vol. 32, № 6. P. 460-466.
11. Kolkhir P. et al. C-reactive protein is linked to disease activity, impact, and response to treatment in patients with chronic spontaneous urticaria // Allergy. 2018. Vol. 73, № 4. P. 940-948.
12. Yan S. et al. C-reactive protein (CRP) rs3093059C predicts poor mizolastine response in chronic spontaneous urticaria patients with elevated serum CRP level // Exp. Dermatol. 2019. Vol. 28, № 3. P. 240-246.
13. Demirkan S., Baççıoğlu A. Rationale for the autologous serum skin test in acute versus chronic urticaria // Postepy Dermatol Alergol. 2019. Vol. 36, № 6. P. 703-706.
14. Ulambayar B. et al. Increased platelet activating factor levels in chronic spontaneous urticaria predicts refractoriness to antihistamine treatment: an observational study // Clin Transl Allergy. 2019. Vol. 9. P. 33.
15. Marzano A.V. et al. Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients // J Eur Acad Dermatol Venereol. 2019. Vol. 33, № 5. P. 918-924.
16. Ertas R. et al. The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change // Allergy. 2018. Vol. 73, № 3. P. 705-712.
17. Cugno M. et al. IgE and D-dimer baseline levels are higher in responders than nonresponders to omalizumab in chronic spontaneous urticaria // Br. J. Dermatol. 2018. Vol. 179, № 3. P. 776-777.
18. Weller K. et al. Total IgE levels are linked to the response of chronic spontaneous urticaria patients to omalizumab // Allergy. 2018. Vol. 73, № 12. P. 2406-2408.
19. Straesser M. D. et al. Serum IgE as an immunological marker to predict response to omalizumab treatment in symptomatic chronic urticaria // J Allergy Clin Immunol Pract. 2018. Vol. 6, № 4. P. 1386-1388.e1.
20. Ertas R. et al. Increased IgE levels are linked to faster relapse in patients with omalizumab-discontinued chronic spontaneous urticaria // J. Allergy Clin. Immunol. 2017. Vol. 140, № 6. P. 1749-1751.
21. Deza G. et al. Basophil FcεRI Expression in Chronic Spontaneous Urticaria: A Potential Immunological Predictor of Response to Omalizumab Therapy // Acta Derm. Venereol. 2017. Vol. 97, № 6. P. 698-704.
22. MacGlashan D. Expression of CD203c and CD63 in Human Basophils: Relationship to Differential Regulation of Piecemeal and Anaphylactic Degranulation Processes // Clin Exp Allergy. 2010. Vol. 40, № 9. P. 1365-1377.
23. Palacios T. et al. Lack of basophil CD203c-upregulating activity as an immunological marker to predict response to treatment with omalizumab in patients with symptomatic chronic urticaria // J Allergy Clin Immunol Pract. 2016. Vol. 4, № 3. P. 529-530.
24. Curto-Barredo L. et al. Basophil Activation Test identifies the patients with Chronic Spontaneous Urticaria suffering the most active disease // Immun Inflamm Dis. 2016. Vol. 4, № 4. P. 441-445.
25. Ghazanfar M. N., Sand C., Thomsen S. F. Effectiveness and safety of omalizumab in chronic spontaneous or inducible urticaria: evaluation of 154 patients // Br. J. Dermatol. 2016. Vol. 175, № 2. P. 404-406.
26. Gericke J. et al. Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria // J. Allergy Clin. Immunol. 2017. Vol. 139, № 3. P. 1059-1061.
27. Asero R. et al. Elevated baseline D-dimer plasma levels are associated with a prompt response to omalizumab in patients with severe CSU // J Allergy Clin Immunol Pract. 2017. Vol. 5, № 6. P. 1740-1742.
28. Nettis E. et al. Omalizumab in chronic spontaneous urticaria: Efficacy, safety, predictors of treatment outcome, and time to response // Ann. Allergy Asthma Immunol. 2018. Vol. 121, № 4. P. 474-478.
29. Hollander S. M., Joo S. S., Wedner H. J. Factors that predict the success of cyclosporine treatment for chronic urticaria // Ann. Allergy Asthma Immunol. 2011. Vol. 107, № 6. P. 523-528.
30. Grattan C. E. et al. Randomized double-blind study of cyclosporin in chronic «idiopathic» urticaria // Br. J. Dermatol. 2000. Vol. 143, № 2. P. 365-372.
31. Endo T. et al. Identification of biomarkers for predicting the response to cyclosporine A therapy in patients with chronic spontaneous urticaria // Allergol Int. 2019. Vol. 68, № 2. P. 270-273.
32. Santiago L. et al. IgE levels are negatively correlated with clinical response to ciclosporin in chronic spontaneous urticaria // Br. J. Dermatol. 2019. Vol. 180, № 1. P. 199-200.
33. Di Gioacchino M. et al. Treatment of chronic idiopathic urticaria and positive autologous serum skin test with cyclosporine: clinical and immunological evaluation // Allergy Asthma Proc. 2003. Vol. 24, № 4. P. 285-290.
Рецензия
Для цитирования:
Переверзина Н.О., Грибалева Е.О., Алленова А.С., Скандер Д.М., Колхир П.В. Потенциальные маркеры ответа на лечение у больных хронической спонтанной крапивницей. Лечащий Врач. 2020;(11):27-31. https://doi.org/10.26295/OS.2020.22.86.006
For citation:
Pereverzina N.O., Gribaleva E.O., Allenova A.S., Skander D.M., Kolkhir P.V. Potential markers of response to treatment of patients with chronic spontaneous urticaria. Lechaschi Vrach. 2020;(11):27-31. (In Russ.) https://doi.org/10.26295/OS.2020.22.86.006
Просмотров: 66
Послать статью по эл. почте 
